FDA granted Orphan Drug Designation for LUMRYZ, a drug developed by Avadel Pharmaceuticals.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Avadel Pharmaceuticals →

  specialty pharmaceutical company

  Nothing else this week.

Related events

• EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Jun 8
• Aurinia's LUPKYNIS received FDA approval on July 31, 2025.Jun 8
• Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.Aug 18